Weymann D, Krebs E, Pollard S, McPhail M, Bosdet I, Yip S, Weppler AM, Karsan A, Anderson H, Bubela T, Law MR, Kesselheim AS, Regier DA - Journal of the National Cancer Institute
- Research Publications
- Price, Value, and Access
Summary:
Expanding coverage for multi-gene panel testing and pembrolizumab in metastatic melanoma patients in British Columbia led to a 111-day increase in two-year patient survival and a mean per-patient cost increase of $53,963. However, these individual gains did not translate into improved population-level mortality, while overall healthcare system costs rose significantly.
VIEW SOURCE
Recent Work from PORTAL
Pharmaceutical Industry Pay-Per-Click Advertising Strategies to Influence Public Opinions on Drug Pricing
Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics
- Research Publications
- Price, Value, and Access
Coverage and Costs for Medications After Medicare Price Negotiation
Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine
- Research Publications
- Price, Value, and Access
Methodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty
Chen NC, Bullement A, Zemplenyi AT, O'Bryant CL, Kaizer AM, Anderson KE, McQueen RB - PharmacoEconomics Open
- Research Publications
- Price, Value, and Access
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.